Awarded Exclusive License from UC San Diego

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer
Biotech Start Up Expands its Oncology Immunotherapeutic Product Pipeline

Productive and beneficial relationships with cutting-edge pharmaceutical companies such as Batu Biologics help speed further development of promising new drugs to those most in need.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Names Chief Scientific Officer

Batu Biologics Names Business Development and R&D Expert as Chief Scientific Officer
International Biotech Market Expert Will Help Boost Company’s Business Strategy

Her impeccable clinical trials expertise, combined with stellar interpersonal skills and keen knowledge of international markets, will serve the company well in its quest to be the first to successfully launch an anti-angiogenic lung cancer vaccine on the market.

Read the full article at businesswire.com

Continue →
0

Achieves Goal in Successful Crowdfunding Campaign

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign
Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine

Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform.

Read the full article at businesswire.com

Continue →
0

Renowned Cancer Immunologist to Scientific Advisory Board

Batu Biologics Recruits Renowned Cancer Immunologist to Scientific Advisory Board
Internationally Recognized Scientist to Assist Company in FDA Development of First Anti-Angiogenic Cancer Vaccine

Having worked in the field of tumor immunology and on the development of the first tumor vaccine to be approved by a regulatory body (Melacine), I am fascinated by novel approaches to cancer immunotherapy.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Launches Crowdfunding Campaign

Batu Biologics Launches Crowdfunding Campaign to Complete Preclinical Testing for VallovaxTM Cancer Therapy
San Diego immunotherapy company seeks to raise $100,000 to complete IND enabling experiments for the FDA

We hope to utilize this crowdfunding campaign as a stepping stone toward larger future campaigns. Batu hopes to not only progress the science behind its anti-angiogenic cancer vaccine, VallovaxTM, but to also capitalize on the non-dilutive investment and support from the surrounding community.

Read the full article at businesswire.com

Continue →
0
Page 4 of 5 12345